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Background/aim: The Wnt/β-catenin pathway has important biological activities, including the differentiation of cells and joint
formations. The aim of our study was to determine the effect of paricalcitol on experimentally induced arthritis.
Materials and methods: Type II collagen combined with Freund’s adjuvant was applied to induce arthritis in Wistar albino female rats.
Paricalcitol (0.3 µg/kg daily) was subcutaneously injected starting 1 day after collagen applications (prophylactic group) or 1 day after
the onset of arthritis (therapeutic group), until day 29.
Results: The 29th day arthritis scores were lower compared to the 13th day scores in the paricalcitol groups (P < 0.05), while they were
higher in the arthritis group (P < 0.05). Marked cartilage-bone destruction and extensive perisynovial inflammation were detected in
the arthritis group. Decreased cartilage-bone destruction and perisynovial inflammation in the paws were observed in the paricalcitol
groups. The tissue mRNA levels of DKK1, Wnt5a, and axin-2 were higher in the arthritis group than in the control group. In the
paricalcitol groups, mRNA expressions were lower than in the arthritis group.
Conclusion: The present study shows that the Wnt/β-catenin signaling pathway is active in arthritis. Moreover, paricalcitol ameliorates
arthritis via inhibiting the Wnt/β-catenin pathway. Paricalcitol and the Wnt/β-catenin pathway are candidates for research in human
rheumatoid arthritis.
Key words: Rheumatoid arthritis, Wnt/beta-catenin signaling pathway, paricalcitol

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease. Synovial inflammation leads to cartilage
destruction and bone erosions in RA; however, the
etiopathogenesis of RA is not yet fully known (1).
Synovial fibroblasts (SFs) and increased secretion of
various cytokines, chemokine, and growth factors play
prominent roles in its pathogenesis. The proliferated SF
activates the inflammatory pathways and leads to the
secretion of matrix metalloproteinases (MMPs) (2–5).
Thus, bone remodeling in RA is defective. It is now clear
that inflammation also impacts osteoblast and osteoclast
differentiation and function. Bone resorption and erosion
are increased owing to increased activity of osteoclasts,
whereas bone formation by osteoblasts is suppressed (6).

The Wnt/β-catenin signaling pathway plays a role in
embryogenesis, limb development, and cell adhesion (7).
Previous studies (8–14) showed that the Wnt/β-catenin
signaling pathway affects the proliferation and functions of
several inflammatory cells and the productions of several
cytokines and chemokines, those having a prominent
effect on the pathogenesis of RA. Moreover, increased
synovial tissue expressions of Wnt5a, Wnt7a, and Wnt10b
have also been documented in patients with RA (8–10).
In vitro Wnt5a and Wnt7a applications enhance the
productions of cytokines including tumor necrosis factor
(TNF)-α, interleukin (IL)-6, IL-8, and IL-15, forming
SFs (8,9). Wnt1 administration induces the synthesis
of pro-MMP3 from SFs (11). On the other hand, Wnt
proteins are expressed by T cells (13). The Wnt/β-catenin
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signalingpathway affects T-cell proliferation (12,13) and
extends the survival of regulatory T cells (14). The levels of
Dickkopf-related protein 1 (DKK1), which is an inhibitor
of the Wnt/β-catenin signaling pathway, are increased in
the sera and synovial fluids of patients with RA (15).
Paricalcitol is an active synthetic analog of vitamin D that
has biological activity similar to that of vitamin D (16,17).
Several recent studies have indicated that paricalcitol
has immunomodulatory and antiinflammatory effects in
various experimental models, except the arthritis model
(18,19). Paricalcitol significantly reduced inflammatory
cytokine levels, such as those of IL-18, IL-6, and TNF-α.
Conversely, it increased serum IL-10 levels (20). Several
recent studies showed that paricalcitol inhibits Wnt/βcatenin signaling and blocks β-catenin-mediated gene
transcription (17).
The aim of the present study was to evaluate the efficacy
of the inhibition of the Wnt/β-catenin signaling pathway
by paricalcitol for prophylactic and therapeutic effects
on an experimental arthritis model of collagen-induced
arthritis (CIA).
2. Material and methods
2.1. Animals
The study protocol was approved by the local ethics
committee. This study was performed on 40 female Wistar
albino rats. They were 8 to 10 weeks old and their weights
were between 200 and 250 g. These rats were purchased
from the Experimental Animal Research Center of Fırat
University. During the experiment, animals were kept at a
temperature of 21 ± 4 °C and humidity of 52 ± 8% with a
12-h light dark cycle.
2.2. Experimental applications
The experimental animals were randomized into four
groups (n = 10): control, arthritis (sham), prophylactic
paricalcitol, and therapeutic paricalcitol groups. Collagen
injections were applied to induce arthritis in the arthritis
and paricalcitol groups. Type II collagen (Sigma-Aldrich,
St. Louis, MO, USA), which was diluted with 0.1 M acetic
acid (1 mg in 1 mL), was emulsified with an equal amount
of incomplete Freund’s adjuvant (Difco Laboratories,
Detroit, MI, USA). The prepared solution (totally 200 µg
to each rat) was intradermally injected into the dorsal
tail (100 µg) and back paws (50 µg to each paw) on the
first day. After seven days, a volume of solution of 100
µg was applied to the dorsal tail (booster). Each rat was
individually evaluated for development of arthritis after
the first collagen injection. Arthritis scorings were done
according to the previously described method (21).
The rats in group III (prophylactic paricalcitol group)
received paricalcitol subcutaneously starting 1 day after
collagen applications. Paricalcitol applications were started
1 day after the onset of arthritis in group IV (therapeutic

paricalcitol group). Since prominent arthritis was observed
in the collagen-injected groups on the 12th and 13th days
(Figure 1), paricalcitol application was started on the 13th
day in the therapeutic paricalcitol group. Paricalcitol at
0.3 μg/kg was given subcutaneously and daily until the
29th day. Physiologic serum (equal volume to paricalcitol)
was injected intraperitoneally in the control and arthritis
(sham) groups (22).
2.3. Samples
The animals were euthanized on the 29th day. Back paws
were amputated for further examination. Joint samples
were divided into two sections for real-time PCR analysis
and histopathological examinations. The section for the
real-time PCR analysis was kept at –80 °C. The other part
was put into 10% formaldehyde for histopathological
examinations.
2.4. Histopathological examinations
Joint samples, which were fixed in a formalin solution,
were decalcified in 10% nitric acid (30 days) and were
embedded in paraffin blocks. Then the sectioned paraffin
blocks were stained with hematoxylin and eosin (H&E).
They were examined under 40×, 100×, 200×, and 400×
magnifications with a light microscope. Pannus formation,
inflammatory cell infiltration, and bone destruction in the
joints were assessed. The inflammatory status and cartilagebone destruction were scored for histopathological scoring
on a scale between 0 and 4 points (23).
2.5. Real-Time PCR analysis
TRIzol reagents (Invitrogen, Carlsbad, CA, USA) were
used to isolate total RNA from joint tissue. cDNA was
generated by reverse transcription of total RNA with a
cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). PCR
reactions were performed in triplicate and heated to 50 °C

Figure 1. Daily arthritis scores in the all study groups. a P < 0.05
when compared to the control group. b P < 0.05 when compared
to both paricalcitol groups. c P < 0.05 when 13th and 29th day
arthritis scores were compared in the Pari 2 group. Pari 1:
Prophylactic paricalcitol group, Pari 2: therapeutic paricalcitol
group.
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for 2 min followed by 40 cycles of denaturation at 95 °C
for 10 min, 95 °C for 15 s, and 60 °C for 1 min. For each
sample, standard curves (cycle threshold values versus
template concentration) were prepared for each target gene
and for the endogenous reference. Real-time PCR analysis,
using Tag Man Master Mix (Applied Biosystems, Foster
City, CA, USA), was performed with the ABI Prism 7500
Fast Real Time PCR Instrument (Applied Biosystems). All
results were standardized to the levels of GAPDH (24). The
comparative Ct (ΔΔCt) method was used to quantify axin2, Wnt5a, and DKK1 genes as described in the Assays-onDemand User’s Manual.
2.6. Statistics
Statistical analysis was performed using the SPSS 21.0
(IBM Corp., Armonk, NY, USA). Kruskal–Wallis variance
analysis and the Mann–Whitney U test were selected for
statistical analysis. The comparison of differences in the
arthritis scoring between the 13th and 29th days was
evaluated with the Wilcoxon rank-sum test. Bonferroni
corrections were performed for multiple comparisons. P <
0.05 was accepted as statistically significant.
3. Results
3.1. Clinical scoring of arthritis
Clinically prominent arthritis was observed at 12 to 13
days after collagen injections (Figure 1). The arthritis
scores were higher in the arthritis (sham), prophylactic
paricalcitol, and therapeutic paricalcitol groups compared
to the control group (P < 0.05 for all). The 29th day arthritis
scores were decreased in the paricalcitol groups compared
to their own 13th day scores (P < 0.05 for both). The mean
29th day arthritis score was increased in the arthritis group
compared to its own 13th day score (P<0.05).
3.2. Histopathological evaluations
Histopathological analysis showed marked cartilage-bone
destruction and extensive perisynovial inflammation in
the rats of the arthritis group, while these findings were
not observed in the rats of the control group (Figure 2).
Prophylactic and therapeutic paricalcitol applications
decreased the cartilage-bone destruction and perisynovial
inflammation in the joints (Figure 2).
3.3. Quantitative real-time PCR analysis
The tissue mRNA expressions of DKK1 (3-fold), Wnt5a
(11-fold), and axin-2 (22-fold) were increased in the
arthritis group compared to the control group. Conversely,
their mRNA expressions were similar in the paricalcitol
groups and the control group (Figure 3).
4. Discussion
The present study demonstrates that the Wnt/β-catenin
signaling pathway is activated in the CIA model, an
experimental model of RA. On the other hand, paricalcitol
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suppresses the Wnt signaling pathway and thus ameliorates
arthritis.
Multiple signaling pathways are activated during RA
development (25). The Wnt/β-catenin signaling pathway
has considerable roles in the pathogenesis of RA (11,26).
In our study, the mRNA levels of axin-2, Wnt5a, and DKK1
were increased in the arthritis group in comparison to the
control group. These results suggest that the Wnt/β-catenin
signaling pathway is activated in arthritis. Recent studies
(9,27) showed that the β-catenin expression in synovial
specimens harvested from RA patients is significantly
higher than in the synovial specimens harvested from
patients with osteoarthritis and healthy adults. β-Catenin
and Wnt5a productions are increased in SFs harvested
from patients with RA (8,11). Wnt/β-catenin pathway
activation contributes to the activation of fibroblast-like
synoviocytes (FLSs) in RA (11,26).
The Wnt/β-catenin pathway participates in many
physiological activities, including cell differentiation,
proliferation, and apoptosis (5). FLSs and inflammatory
cells have prominent roles in the pathogenesis of RA
(1,4,6). The activation changes the phenotype of FLSs.
Active FLSs produce cytokines, chemokines, and MMP.
The other pathogenic actors are inflammatory cells
that invade synovial tissue, and activated/proliferated
inflammatory cells also produce cytokines, chemokines,
and MMP (1,4,6). The Wnt/β-catenin pathway is a
candidate to affect activation, proliferation, and migration
of inflammatory cells and FLSs. In in vitro settings it
has been observed that when Wnt proteins are applied
to the synovial cells harvested from control subjects, the
productions of proinflammatory cytokines, which are IL1, IL-6, and TNF-α, are enhanced (9). These cytokines are
known to play an important role in RA pathogenesis. RA is
an inflammatory disease, and cytokines are the prominent
process of the RA pathogenesis.
Wnt proteins and Wnt/β-catenin signaling pathwayinduced proteins such as DKK1 can be produced by
inflammatory cell, and they affect the inflammatory
cells. Previous findings showed that the Wnt/β-catenin
signaling pathway is activated in RA synovium and that
the activated Wnt/β-catenin signaling pathway enhances
the production of proinflammatory cytokines such as IL1, IL-6, and TNF-α (10,11). Similarly, increased Wnt1,
Wnt5a, and Wnt7b in FLSs from RA patients induce the
production of these cytokines and MMP3 (28). Moreover,
when Wnt5a is silenced with siRNA the cytokine and
chemokine productions significantly decrease (29).
In addition to inflammatory roles, the Wnt signaling
pathway has an important regulative role in the balance of
the osteoblast and osteoclast axis. The disturbed balance
of osteoblasts and osteoclasts is one component of the
pathogenesis of RA and leads to bone resorption and
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Figure 2. Histopathological sections of joints in the study groups (H&E, 400×). The appearances of perisynovial tissue and cartilage-bone
were normal in the control group (A). The destruction of cartilage-bone was observed in the arthritis group (B). Minimal perisynovial
inflammation and synovial hyperplasia were detected in the prophylactic (C) and therapeutic (D) paricalcitol groups. The destruction of
cartilage-bone is marked by arrows and the inflammatory cell infiltrations and synovial hyperplasia are marked by asterisks.

erosion (1). There are different roles of the Wnt/β-catenin
signaling pathway in the functions and differentiations
of osteoblasts and osteoclasts. Thus, the Wnt/β-catenin
signaling pathway has a pivotal role on bone turnover
and the regulation of cartilage (30). In our study, it was
observed that the Wnt/β-catenin signaling pathway is
activated in experimentally induced arthritis.
Paricalcitol blocks β-catenin accumulation and
activation mediated by its ability to inhibit the expression
of multiple Wnt genes and to inhibit β-catenin-mediated
gene transcriptions (16,17). It has also been shown that
paricalcitol inhibits the production of proinflammatory
cytokines and reduces the inflammatory cell infiltration
of the kidneys. Treatment with paricalcitol attenuates
inflammation and oxidative damage in animal models
(17). Some reports showed that vitamin D deficiency
has been linked to an increased incidence of RA and

suggested that vitamin D supplementation might prevent
the development of these diseases. In addition, a few
scientists presented a hypothesis that paricalcitol can be
used in combination with biological agents for treating
RA, by improving the therapeutic efficacy of biologic
agents and decreasing the incidence of infection (31).
In the present study, paricalcitol ameliorated synovial
hyperplasia, pannus formation, and cartilage-bone
destruction. In addition, paricalcitol reduced the arthritis
scores. Moreover, paricalcitol decreased Wnt5a expression
in our study. These results may suggest that paricalcitol
exerts antiarthritic action and depletes the Wnt signaling
pathway.
Additionally, higher levels of several Wnt proteins
such as Wnt1 and Wnt5a have been shown in FLSs and
synovial tissue specimens from RA patients than in the
osteoarthritis patients and healthy controls (8). Several
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Figure 3. Tissue mRNA expressions of axin-2, Wnt5a, and DKK1 in the study groups. Cntrl: Control, Pari 1: prophylactic paricalcitol
group, Pari 2: therapeutic paricalcitol group, DKK1: Dickkopf-1.

studies showed that Wnt5a-mediated intracellular
signaling in RA aggravates the production of inflammatory
cytokines, chemokines, MMPs, and angiogenic factors
(7,8,11). While increased Wnt5a expression upregulates
the expression of cytokines and chemokines, decreased
Wnt5a expression reduces their synthesis and secretion.
The Wnt5a-mediated production of the cytokines and
chemokines was at least partly induced by NF-κB.
Moreover, the Wnt5a-mediated signaling pathway can also
promote angiogenesis of the synovium by upregulating
angiogenic regulators (28). Recent studies have also
shown that Wnt5a enhanced osteoclast formation (32).
Dickkopf-1, an endogenous inhibitor of Wnt/βcatenin signaling, is secreted by FLSs in response to
inflammation in RA. DKK1 is important for the balance
of osteoblasts and osteoclasts and it repairs bone damage
in RA (31). The levels of DKK1 were significantly higher
in RA patients and increased DKK1 inhibits the Wnt/βcatenin signaling pathway in osteoblasts. Thus, DKK1
inhibits the osteoblastic differentiation in RA. In an
experimental model of RA, blockade of DKK1 attenuated
bone erosion to induce new bone formation (15,28,33).
In our study, the tissue mRNA expression of DKK1 was
greatly increased in the arthritis group compared to
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the control group. DKK1 expressions were decreased
with administration of paricalcitol and were similar in
the paricalcitol and control groups. These observations
show that DKK1 might be an interesting new structural
biomarker in early RA and DKK1 may be a promising
therapeutic target in RA.
Axin-2 is a negative regulator and a target of Wnt/βcatenin signaling. Axin-2 is expressed in cell populations
responsive to Wnt/β-catenin signaling. T-cell factor
proteins played a key role in axin-2 induction. The increase
in axin-2 expression in the arthritis group and decrease in
paricalcitol groups may be associated with this interaction
in parallel with the Wnt/β-catenin pathway (34).
The present study has several limitations. First, it
documents the early effects of paricalcitol applications
on arthritis; however, its long-term effects should also be
researched. Second, radiographic progressions need to be
evaluated.
In conclusion, these results show that the Wnt signaling
pathway is active in arthritis. Moreover, paricalcitol
inhibits the Wnt/β-catenin signaling pathway and thus
ameliorates arthritis. Paricalcitol and the Wnt/β-catenin
signaling pathway are candidates for further research in
human RA.
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